EFFECT OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND ENDOTHELIN RECEPTOR ANTAGONIST ON NITROGLYCERIN TOLERANCE IN RATS

被引:0
|
作者
张建梅
陈永红
王晓红
唐朝枢
机构
关键词
angiotensin II receptor antagonist; endothelin receptor antagonist; nitroglycerin;
D O I
暂无
中图分类号
R965 [实验药理学];
学科分类号
100602 ; 100706 ;
摘要
Objective. To investigate whether angiotensin II receptor antagonist and endothelin receptor antagonist can improve the nitroglycerin (Nit) tolerance in vivo. Methods. Twenty- four rats were divided into 4 groups (n=6,each): Control group, Nitroglycerin (Nit) group, Nit+ bosentan group and Nit+ losartan group. Nitroglycerin tolerance was induced by 2- day treatment of nitroglycerin patch (0.05 mg/h). AngiotensinⅡ receptor antagonist losartan ( 10 mg· kg- 1· d- 1 ) and endothelin receptor antagonist bosentan ( 100 mg· kg- 1· d- 1 ) were given by gavage for 2 days respectively. Results. The least hypotensive response to sodium nitroprusside (SNP) was observed in Nit group . The effective percentages of hypotensive response to SNP were increased in both Nit+ losartan group and Nit+ bosentan group compared with Nit group [(31.95± 4.45 )% vs (21.00± 3.69 )% , P< 0.01 and (33.18± 6.16 )% vs (21.00± 3.69 )% , P< 0.01 ,respectively]. The maximal vessel relaxation induced by SNP was the same in 4 different groups but the highest EC50 (concentration which produces 50% of the maximal response to SNP) was found in tolerant group[(34± 10) nmol/ L,P < 0.01 .The ET- 1 amounts in plasma and vascular tissue were markedly increased by 54% and 60% in Nit group compared with those in control group(P< 0.01).The ET- 1 amounts in plasma and vascular tissue were decreased by 30% and 37% in Nit+ losartan group compared with those in Nit group (P< 0.01). Conclusion. Endothelin receptor antagonist and angiotensinⅡ receptor antagonist could prevent against the Nit tolerance .
引用
收藏
页码:82 / 85
页数:4
相关论文
共 50 条
  • [1] The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin
    Milone, SD
    Azevedo, ER
    Forster, C
    Parker, JD
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (05) : 645 - 650
  • [2] Antiproteinuric effect of angiotensin II receptor antagonist
    Kajioka, T
    Ueno, M
    Tsuchihashi, T
    Tominaga, M
    Goto, K
    JOURNAL OF HYPERTENSION, 2002, 20 : S366 - S366
  • [3] Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man
    Wenzel, RR
    Rüthemann, J
    Bruck, H
    Schäfers, RF
    Michel, MC
    Philipp, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (02) : 151 - 157
  • [4] Angiotensin II Receptor Antagonist in Pregnancy
    Patrice Morville
    Journal of Perinatology, 2004, 24 (1) : 56 - 57
  • [5] Balanced angiotensin II receptor antagonist
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (05) : 218 - 218
  • [6] Angiotensin II-Receptor Antagonist Losartan Does not Prevent Nitroglycerin Tolerance in Patients with Coronary Artery Disease
    Giancarlo Longobardi
    Nicola Ferrara
    Dario Leosco
    Pasquale Abete
    Giuseppe Furgi
    Francesco Cacciatore
    Graziamaria Corbi
    Raffaella Pescatore
    Franco Rengo
    Cardiovascular Drugs and Therapy, 2004, 18 : 363 - 370
  • [7] Angiotensin II-receptor antagonist Losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease
    Longobardi, G
    Ferrara, N
    Leosco, D
    Abete, P
    Furgi, G
    Cacciatore, F
    Corbi, G
    Pescatore, R
    Rengo, F
    CARDIOVASCULAR DRUGS AND THERAPY, 2004, 18 (05) : 363 - 370
  • [8] Endothelin receptor antagonist
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1997, 2 (12) : 554 - 554
  • [9] Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist
    Chiu, Ada W.
    Bredenkamp, Nina
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (06) : 645 - 656
  • [10] Antiproteinuric effect of an angiotensin II receptor antagonist in membranous nephropathy
    Miyauchi, N
    Nakamura, Y
    NEPHRON, 2001, 88 (02): : 183 - 184